WeightWatchers has conducted a 6-month clinical trial of 180 participants on GLP-1 medication (Heinberg et al.), but the manuscript is under review and has not yet been published in a peer-reviewed journal
Buse JB, Crowley M, Eriksson JW, Gislum M, Hertz CL, Kaiser M, et al
*Compounded medications have not been evaluated or approved by the FDA for safety, efficacy, or quality
Any type of restriction and restrictive behavior is going to put somebody at risk for an eating disorder, Spann said
Body composition analysis with InBody provides: Accurate BMR measurement for personalised nutrition planning during GLP-1 therapy Visceral fat assessment for metabolic disease risk evaluation at each visit Muscle mass tracking to prevent metabolic slowdown and sarcopenia Phase angle monitoring for cellular health across the treatment course Water distribution analysis for detecting inflammation and fluid imbalance This comprehensive metabolic assessment is alone, and it is now the clinical standard of care in progressive metabolic medicine globally
This is just an example to help you understand the idea
